Docoh
Loading...

Mon. 22 Nov 2021, 9:28am ETBenzinga
In: News, Price Target, Analyst Ratings
Credit Suisse analyst Tiago Fauth maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $100 to $105.